As we know, therapies that target some but not all antigens in a tumor, I believe IMUC was one of them, have been tried but have not proven to be effective. IMUC's therapy was not approved, but as someone on this board pointed out, it may have been Flipper, they could have identified the subset for which it did work and then move forward with that subset.
Can you find one single BP that doesn't have the acquisitions on ADCs and T-cell engagers? I cannot find one. Both ADCs and T-cell engagers require precise information on the tumor targets. IMO, that's what the precision medicine is about. Can DCVax-L platform help BPs to do the target identification? Absolutely.
Anyone who still has doubt can go to the following webpage, download the data, pick up the target adopted by the current available ADCs, locate the target in the downloaded data, and check the variation of those targets before and after the treatments. https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE237579
But I suspect ADCs cannot work for all tumors since tumor-specific targets cannot be found for all tumors. Then it is up to DCVax-L to eliminate those tumors.
News 
Market Data 
Discover 
